PeLeMed
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PeLeMed - overview
Established
2019
Location
Gwangju, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2019 and based in Gwangju, South Korea, PeLeMed is a drug research and development company on cancer, nerve, immune diseases, and new drug development. In March 2023, PeLeMed raised KRW 5. 5 billion in venture funding from new investors BSK Investment, Bokwang Venture Investment, and Alpha One Investment, with participation from returning investors KDB Capital and LSK Investment. As of 2023, the company is led by its co-CEO Kim Yong-cheol and Jang Su-yeon.
The company will use the March funding to conduct phase 1 clinical IND of PLM-102 simultaneously in Korea and the US.
Current Investors
KDB Capital, Samho Green Investment, Daekyo Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.pelemed.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.